Skip to main content

Table 2 Multivariate regression analysis to predict relapse during the 12 months after discontinuation of biologic disease-modifying antirheumatic drug therapy

From: Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled

  Comparison OR 95% CI p Value
Sex Female vs. male 0.25 0.02 1.79 0.17
SDAI at initiation of bDMARD 1 increase 0.95 0.88 1.03 0.20
Bone erosion by ultrasound Presence vs. absence 8.35 1.78 53.2 0.017
  1. bDMARD Biologic disease-modifying antirheumatic drug; SDAI Simplified Disease Activity Index
  2. Variables with a p value less than 0.02 in Table 1 were used in multivariate models